Thermo Fisher Scientific Inc. (NYSE:TMO) Holdings Raised by Nichols & Pratt Advisers LLP MA

Nichols & Pratt Advisers LLP MA raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 20,523 shares of the medical research company’s stock after buying an additional 1,434 shares during the period. Nichols & Pratt Advisers LLP MA’s holdings in Thermo Fisher Scientific were worth $11,349,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the stock. Norges Bank bought a new position in Thermo Fisher Scientific during the 4th quarter valued at $2,909,524,000. Capital World Investors grew its holdings in Thermo Fisher Scientific by 10.0% during the first quarter. Capital World Investors now owns 13,493,852 shares of the medical research company’s stock worth $7,842,762,000 after acquiring an additional 1,231,059 shares during the period. Swedbank AB bought a new stake in Thermo Fisher Scientific in the first quarter worth about $705,636,000. Veritas Asset Management LLP lifted its holdings in Thermo Fisher Scientific by 70.1% in the 4th quarter. Veritas Asset Management LLP now owns 1,692,148 shares of the medical research company’s stock valued at $898,175,000 after acquiring an additional 697,383 shares during the last quarter. Finally, Winslow Capital Management LLC acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $333,786,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on TMO. Stifel Nicolaus raised their target price on shares of Thermo Fisher Scientific from $600.00 to $615.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Robert W. Baird boosted their target price on Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Jefferies Financial Group reiterated a “buy” rating and issued a $650.00 price target (up previously from $600.00) on shares of Thermo Fisher Scientific in a research report on Monday, June 3rd. TD Cowen upped their price objective on shares of Thermo Fisher Scientific from $648.00 to $658.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Finally, HSBC lifted their target price on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th. Five investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $618.94.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total value of $5,672,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at approximately $70,238,340.48. The sale was disclosed in a filing with the SEC, which is available at this link. In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction on Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $180,255.00. Following the completion of the transaction, the executive vice president now directly owns 17,887 shares in the company, valued at $10,747,403.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $567.28, for a total transaction of $5,672,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $70,238,340.48. The disclosure for this sale can be found here. Insiders sold a total of 33,084 shares of company stock valued at $19,767,092 over the last ninety days. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Up 0.4 %

Shares of TMO traded up $2.26 during midday trading on Friday, reaching $606.12. 777,265 shares of the stock were exchanged, compared to its average volume of 1,530,541. The company has a market cap of $231.37 billion, a price-to-earnings ratio of 38.88, a P/E/G ratio of 2.81 and a beta of 0.77. The firm has a 50 day simple moving average of $574.15 and a 200-day simple moving average of $573.81. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $622.30. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, topping the consensus estimate of $5.13 by $0.24. The firm had revenue of $10.54 billion for the quarter, compared to the consensus estimate of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The business’s quarterly revenue was down 1.4% on a year-over-year basis. During the same period in the prior year, the business posted $5.15 earnings per share. Research analysts forecast that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be paid a $0.39 dividend. The ex-dividend date is Friday, September 13th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.26%. Thermo Fisher Scientific’s payout ratio is 10.01%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.